American Healthcare REIT

step: 01 title: Business Model & Overview ticker: AHR company: American Healthcare REIT, Inc. source: coverage-next-full sector_track: REIT created: 2026-06-08

Step 01 — Business Model: American Healthcare REIT (AHR)

1. Business Description

American Healthcare REIT is an internally managed, NYSE-listed real estate investment trust that owns and operates a diversified portfolio of healthcare properties across the United States [S1]. The company's portfolio is organized into three operating segments — Integrated Senior Health Campuses (ISHC), Senior Housing Operating Properties (SHOP), and Outpatient Medical (OM) — representing a continuum from heavy-care skilled nursing to lighter-touch independent living and clinical outpatient care [S1].

The company's predecessor entities (Griffin-American Healthcare REIT III and IV) operated as non-traded REITs from 2013 onwards, merging in 2021 and listing on the NYSE in February 2024 [S1][S2]. Approximately $1.36B in equity was raised at IPO and follow-on (September 2024), enabling the company to pay down ~$1B of high-cost debt and shift its capital structure materially [S2].

The defining strategic characteristic is internal management: unlike most US healthcare REITs, AHR has no external adviser. Management was internalized in 2021 via an approximately $131.7M OP-unit transaction with co-founders and Griffin Capital. This eliminates advisory fees that typically run 0.5–1.5% of assets per year for externally managed peers [S5].

2. Value-Chain Layer Map

Healthcare Need (aging population demand)
          ↓
Property / Real Estate Layer (AHR owns)
   ├── ISHC / Trilogy (owned + operated)
   │     ├── Skilled Nursing Facilities (SNF)
   │     ├── Assisted Living (AL)
   │     ├── Independent Living (IL)
   │     └── Ancillary (pharmacy, therapy, home health)
   ├── SHOP (owned; third-party operators manage)
   │     ├── Assisted Living
   │     ├── Memory Care
   │     └── Independent Living
   └── Outpatient Medical / MOB (owned; NNN + gross leases)
         ├── Medical Office Buildings
         ├── Outpatient Surgery Centers
         └── Specialty Clinic Space
          ↓
Capital Layer (equity + debt financing)
   ├── Common equity (NYSE: AHR ~$8B market cap)
   ├── Revolving credit facility ($600M)
   └── Term loans + mortgage debt (~$1.5B total)
          ↓
Returns to Shareholders (dividends + NFFO growth)

3. Segment Deep Dive

ISHC / Trilogy (Dominant Segment, ~60% of Revenue)

Trilogy Healthcare is a consolidated operating subsidiary — AHR owns 100% following the September 2024 acquisition of NorthStar's remaining 24% minority interest for ~$258M [S2]. Trilogy operates 147 properties concentrated in Indiana, Ohio, Michigan, and Kentucky, providing a full continuum of senior care [S1][S2].

The RIDEA structure means AHR captures both the NOI from real estate and operating income/losses from the healthcare business — higher upside vs. NNN leases, but also direct exposure to staffing costs, labor markets, and Medicare/Medicaid reimbursement [S1]. Trilogy's differentiation: (1) integrated campus model reduces resident transfer (IL→AL→SNF on one campus, avoiding third-party SNF admission), (2) ancillary revenue streams (pharmacy, therapy, home health) add ~$40–60M in incremental annual revenue, (3) strong Midwest referral network from hospital partnerships.

Q4 2025 occupancy: 90.6% — above pre-COVID levels and above industry SNF averages (~78%) [S2].

SHOP (Growth Segment, ~20% of Revenue)

83 properties operated under RIDEA by third-party operators including Discovery Senior Living and Integral Senior Living [S2]. Geographic mix skewed toward Sunbelt states (Florida, Texas, Arizona) and Pacific Coast. Occupancy has been recovering sharply: Q1 2026 same-store NOI growth +19.7% YoY, reflecting combination of occupancy recovery and rate increases [S2].

Unlike ISHC, AHR does not operate SHOP assets directly — it relies on operator execution. Operator selection and monitoring is a key governance risk.

Outpatient Medical / MOB (~20% of Revenue)

71 outpatient medical properties with 22.2M sqft GLA [S1]. These are predominantly long-term NNN or gross leases to health systems (e.g., HCA, Ascension) and independent physician groups. Lease terms typically 7–15 years with annual CPI escalators. Lowest volatility segment; provides cash flow stability. Cap rates for hospital-anchored MOBs run 6.0–6.5% — compressed vs. history but still favorable vs. senior housing pricing [S4].

4. Revenue Model

AHR generates revenue through two primary economic models:

RIDEA (80% of revenue): AHR consolidates the full P&L of ISHC and SHOP properties. Revenue is the gross healthcare facility revenue (room charges, ancillary fees, Medicare/Medicaid). Operating expenses (labor, supplies, overhead) are deducted within the segment. This produces higher absolute revenue and EBITDA but requires management of operational complexity [S1].

NNN/Gross Leases (~20% of revenue): Outpatient Medical properties generate contractual rental income with minimal operating expense at the REIT level. Highly predictable cash flows with CPI-escalated rent bumps [S1].

The strategic shift from NNN senior housing to RIDEA has been central to the AHR story: post-COVID, operators were under-performing under NNN structures, leading AHR to convert leases to RIDEA or acquire operators directly. This increased risk but also captures the full recovery in senior housing economics [S2].

5. Business Cycle Positioning

Healthcare real estate sits in a favorable secular window as of 2026 [S4]:

• 80+ population growing 48% by 2030 (oldest Baby Boomers turn 80 in 2026)
• Senior housing supply growth near all-time lows (~1% inventory growth, units under construction at 2012 lows)
• Occupancy in assisted living/memory care recovering toward 90%+ from COVID trough (~78%)
• Medical office benefiting from outpatient shift in healthcare delivery

AHR is early in its public company lifecycle (listed February 2024), with a NFFO growth path that is partially balance-sheet-driven (deleveraging reducing interest expense) and partially operational (occupancy recovery + same-store NOI compounding). FY2026 NFFO guidance: $2.02–$2.09/share (+17–21% YoY) [S2].

6. Key Business Risks at the Model Level

Source Index

step: 04 title: Financial Quality & Adversarial Sweep ticker: AHR company: American Healthcare REIT, Inc. source: coverage-next-full sector_track: REIT created: 2026-06-08

Step 04 — Financial Quality: American Healthcare REIT (AHR)

1. Statement Quality Assessment

Income Statement Quality

AHR's income statement reflects the complexity of a RIDEA-heavy REIT: revenue includes full operating revenue of healthcare facilities (room charges, ancillary fees), while expenses include direct healthcare labor and supplies. This is economically correct under GAAP but makes margin comparisons vs. NNN peers misleading.

Key adjustments needed:

• Depreciation (D&A, ~$290M FY2025): Real estate depreciation is non-cash and economically overstated for well-maintained properties; standard add-back in NAREIT FFO
• Gain/loss on real estate: $66M gain in FY2025 from property dispositions — non-recurring; excluded from NFFO [S1]
• Impairments: Pre-IPO periods (FY2021–2023) contained property impairment charges; now diminished
• Transaction costs: M&A and capital transaction costs excluded from NFFO; ran ~$20–40M in IPO/follow-on years [S1]
• SBC: ~$25–30M annually; excluded from NFFO; relatively modest at <2% of revenue [S1]
• Interest expense reduction: FY2025 interest expense ~$155M (vs. $226M in FY2023) — structural improvement from debt paydown, not manipulation [S1]

Accounting quality: GOOD. GAAP-to-NFFO bridge is clean and well-disclosed. Management's NFFO reconciliation is comprehensive and consistent with NAREIT guidance.

Balance Sheet Quality

Goodwill ($550M): Arose primarily from the 2021 GAHR III/IV merger and Trilogy acquisition/internalization. Represents ~9% of total assets. Not being amortized (GAAP). Impairment risk is manageable given Trilogy's operational momentum. [Judgment — Medium confidence]

Accumulated deficit ($1.4B): A legacy of pre-IPO losses and large distribution payments that exceeded GAAP earnings (common for non-traded REITs pre-listing). Does not indicate balance sheet distress. Post-IPO equity issuances ($2.5B+ combined) have substantially rebuilt equity.

Balance sheet quality: GOOD. Leverage is conservative for a REIT at 3.0x Net Debt/EBITDA; liquidity of $1.14B (revolver + cash) provides ample coverage. Main risk: continued acquisition activity could re-lever the balance sheet.

Cash Flow Statement Quality

FCF inflected positive in FY2024–2025 post-IPO, validating the thesis that high interest costs were the primary earnings drag. The large distribution payments vs. FCF gap is typical for growth REITs paying dividends ahead of full operating stabilization.

Cash flow quality: GOOD. Operating CF growing rapidly; maintenance capex reasonable at ~5% of revenue. Growth capex ($950M+ in FY2025) funded from equity raises, not operating cash flow.

2. Adversarial Research Sweep

This section documents potential financial risks, short arguments, litigation, regulatory actions, and adverse public interest research discovered through web search. Note: no earnings transcript analysis was performed (coverage-next-full path).

2a. Short Interest & Short Reports

Short interest: No prominent active short reports found for AHR as of mid-2026. Short interest is relatively modest for a recently-listed REIT; the stock rose ~548% from IPO price to market cap peak [S2][S3].

No published short-seller research found targeting AHR-specific accounting concerns.

2b. Regulatory/Legal Actions

No material litigation or regulatory actions identified from public filings review (10-K risk factors + 8-K material events). AHR disclosed the following items in FY2025 10-K risk factors [S1]:

• Routine regulatory compliance risks for healthcare facilities (CMS surveys, state licensing)
• Standard REIT-related tax and compliance risks
• No ongoing material SEC investigations or DOJ actions disclosed

CMS enforcement risk: SNF facilities are subject to CMS survey inspections; deficiency citations can lead to Immediate Jeopardy (IJ) findings that temporarily restrict admissions. Trilogy has had isolated IJ citations historically (common in SNF industry); no systemic enforcement pattern identified. [Judgment]

2c. Related-Party / Governance Concerns

Management internalization (2021): The co-founders (Hanson, Prosky) received ~$131.7M in OP units to internalize management from the Griffin Capital advisory arrangement [S5]. This was a one-time transaction standard for non-traded REIT listings; the economic terms were disclosed in the 2024 prospectus.

NorthStar Trilogy acquisition (Sep 2024): AHR acquired NorthStar's 24% stake in Trilogy for ~$258M — a related-party transaction (NorthStar was a co-investor). The transaction was reviewed by the independent board committee and the price was disclosed as being based on an independent appraisal [S2][S5].

Assessment: No red flags. Both transactions are disclosed, arm's-length reviewed, and economically rational.

2d. CEO Medical Leave

AHR disclosed on February 3, 2026 that CEO Jeff Hanson was placed on medical leave [S2]. Co-founder Danny Prosky stepped in as Interim CEO. Hanson co-founded the company; his absence creates management continuity uncertainty if the leave becomes permanent. The board has not disclosed any succession plan. This is a moderate governance risk that should be monitored.

2e. Pre-IPO Non-Traded REIT History

AHR's predecessor entities were non-traded REITs (GAHR III and GAHR IV) — a structure associated with high upfront selling commissions (typically 7–10% of capital raised) paid to broker-dealers. These fees were borne by the original non-traded REIT investors and did not benefit the listed company. No ongoing liability to AHR [S1][S5].

2f. Trilogy Consolidation Risk

The decision to consolidate Trilogy from NNN to full RIDEA (effectively operating the healthcare business) exposes AHR to labor, regulatory, and Medicare/Medicaid operational risks that a passive NNN landlord would not bear [S1]. This is the appropriate trade-off for the higher NOI, but it is a genuine source of operational complexity not present in MOB-focused or NNN-only peers.

2g. Adversarial Summary

Adversarial Sweep Conclusion: No material adverse findings. The company's financial statements appear to be a fair representation of operations. Key monitoring items: CEO succession and Trilogy operational execution.

Assumption Register Updates

Source Index